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Maspin, a member of the serpin family, has a role in cell migration, angiogenesis and apoptosis. Little is known of the clinical
significance of maspin gene expression in human cancers. We developed a real-time quantitative RT–PCR assay to quantify the full
range of maspin mRNA copy numbers in a series of 10 ERa-positive and 10 ERa-negative breast tumours. We observed a statistical
link between low maspin mRNA levels and positive oestrogen status (P¼0.0012). In consequence, to better assess the prognostic
value of maspin gene expression in breast cancer, we then quantified maspin mRNA content in an additional independent well-
defined cohort of 105 ERa-positive postmenopausal breast cancer patients treated with primary surgery followed by adjuvant
tamoxifen alone. Maspin expression varied widely in tumour tissues (by nearly four orders of magnitude), being underexpressed in 33
out of 105 tumours (31.4%) and overexpressed in 24 out of 105 tumours (22.9%) relative to normal breast tissues.
Immunohistochemical studies demonstrated that maspin protein was strictly expressed in myoepithelial cells of normal breast tissue
and in tumour epithelial cells, exclusively in maspin-overexpressing tumours. Patients with tumours overexpressing the maspin gene
had significantly shorter relapse-free survival after surgery than patients whose tumours normally expressed or underexpressed
maspin (P¼0.0011). The prognostic significance of maspin overexpression persisted in Cox multivariate regression analysis
(P¼0.0024). These findings show that the maspin mRNA level can have important prognostic significance in human breast cancer,
and point to the maspin gene as a putative molecular predictor of hormone responsiveness in breast cancer.
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Maspin (mammary serpin) is a 42-kDa cytoplasmic protein
belonging to the serpin family of serine protease inhibitors (Zou
et al, 1994). The maspin gene was originally identified in normal
mammary epithelium by subtractive hybridisation on the basis of
its expression at the mRNA level (Zou et al, 1994). Maspin has
subsequently been localised to epithelial and myoepithelial cells in
a variety of tissues (Pemberton et al, 1997).
Biological studies suggest a tumour-suppressive role of maspin,
mediated by effects on cell migration (Zou et al, 1994; Sheng et al,
1996), angiogenesis (Zhang et al, 2000a) and apoptosis (Zhang et al,
2000b; Jiang et al, 2002). Maspin expression in breast tumour cells
reduces tumour induction and metastasis in nude mice (Zou et al,
1994; Shi et al, 2001; Streuli, 2002), and also invasion of the
basement membrane in vitro (Zou et al, 1994). Moreover,
treatment of human breast cancer cells with recombinant maspin
(rMaspin) inhibits cell motility (Sheng et al, 1996). Possible
molecular targets for maspin are tissue-type plasminogen activator
(tPA) (Sheng et al, 1998) and various integrins (Seftor et al, 1998).
The role of maspin in human breast cancer is poorly
documented, and even less is known about the clinical significance
of maspin expression in this setting. The few available data on
maspin expression in breast cancer have been obtained using
breast cancer cell lines and breast tumour series (Zou et al, 1994;
Jiang et al, 1997; Domann et al, 2000; Maass et al, 2001a), and the
results are confusing. Indeed, maspin expression is generally
downregulated in primary breast tumours and lost in mammary
carcinoma lines (Zou et al, 1994; Hojo et al, 2001; Maass et al,
2001a,b), but some infiltrating breast tumours have been found to
show strong upregulation (Hojo et al, 2001; Maass et al, 2001b).
Maspin expression has been found to decrease with increasing
malignancy in primary breast tumours, and to be absent from
distant metastases (Zou et al, 1994). Surprisingly, Martin et al
(2000), using cDNA array technology, identified the maspin gene
as the leader of a cluster of genes that are strongly upregulated in
ERa-negative breast tumours (ERa negativity is associated with
aggressive tumours). Finally, four recent clinical studies of
heterogeneous series of women with breast tumours examined
the possible association between maspin expression (mRNA or
protein level) and classical clinical and pathological parameters,
including patient outcome (Hojo et al, 2001; Maass et al, 2001a,b).
The results of these studies are conflicting, three studies suggested
that maspin underexpression could be a potential poor prognostic
marker in breast cancer, while the fourth identified maspin
overexpression rather as an independent poor prognostic indicator
in breast cancer patients (Umerika et al, 2002).
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yHere, we developed a real-time quantitative RT–PCR assay to
quantify maspin mRNA in homogeneous total RNA solutions
obtained from human tissue samples. As we found that maspin
gene expression was strongly linked to ERa expression status, we
quantified maspin mRNA expression in a well-defined cohort of
105 ERa-positive postmenopausal breast cancer patients who were
treated with primary surgery, followed by adjuvant tamoxifen
alone and whose long-term outcome was known. The significance
of maspin as a prognostic factor is discussed.
MATERIALS AND METHODS
Patients and samples
We analysed tissue samples from primary breast tumours excised
from 105 women at Centre Rene ´ Huguenin from 1980 to 1994.
Tumour tissue samples of the 105 patients were collected in
accordance with French regulations.
Immediately following surgery, the tumour samples were stored
in liquid nitrogen until RNA extraction. The patients (mean age
70.8 years, range 54–86) met the following criteria: primary
unilateral nonmetastatic postmenopausal breast carcinoma; oes-
trogen receptor alpha positivity (as determined at the protein level
by biochemical methods (dextran-coated charcoal method until
1988 and thereafter EIA) and confirmed by ERa real-time
quantitative RT–PCR assay); complete clinical, histological and
biological information available; no radiotherapy or chemotherapy
before surgery; and full follow-up at Centre Rene ´ Huguenin.
Among the 105 breast tumours, 97 were invasive ductal
carcinomas and eight were invasive lobular carcinomas. The
standard prognostic factors are presented in Table 1. A total of 34
patients (32.4%) had modified radical mastectomy and 71 (67.6%)
had breast-conserving surgery plus locoregional radiotherapy.
Patients underwent physical examinations and routine chest
radiography every 3 months for 2 years, then annually. Mammo-
grams were performed annually. The median follow-up was 6.0
years (range 1.5–10.0 years). All the patients received post-
operative adjuvant endocrine therapy (tamoxifen, 20mg daily for
3–5 years), and no other treatment. In all, 31 patients relapsed (the
distribution of first relapse events was as follows: 27 metastases,
and four both local and/or regional recurrences and metastases).
To investigate the relation between maspin mRNA levels and
ERa expression status, we also analysed 20 additional primary
breast tumours: 10 ERa-negative and 10 ERa-positive tumours.
We analysed six breast tumuor cell lines obtained from the
American Tissue Type Culture Collection (SK-BR-3, T-47D, BT-20,
HBL-100, ZR-75-1 and MCF7).
Specimens of adjacent normal breast tissue from five of the
breast cancer patients, and normal breast tissue from three women
undergoing cosmetic breast surgery, were used as sources of
normal RNA.
Real-time RT–PCR
Theoretical basis Reactions are characterised by the point during
cycling when amplification of the PCR product is first detected,
rather than the amount of PCR product accumulated after a fixed
number of cycles. The higher the starting copy number of the
target transcript, the earlier a significant increase in fluorescence is
observed. The parameter Ct (threshold cycle) is defined as the
fractional cycle number at which the fluorescence generated by the
incorporation of a fluorogenic molecule in double-stranded DNA
passes a fixed threshold above baseline.
The precise amount of total RNA added to each reaction mix
(based on optical density) and its quality (i.e. lack of extensive
degradation) are both difficult to assess. We therefore also
quantified transcripts of the gene coding for the TATA box-
binding protein (TBP) (a component of the DNA-binding protein
complex TFIID) as the endogenous RNA control, and each sample
was normalised on the basis of its TBP content.
The relative maspin gene expression level was also normalised to
a calibrator, or 1 sample, consisting of a pool of normal breast
tissue specimens.
Final results, expressed as N-fold differences in maspin gene
expression relative to the TBP gene and normal breast tissues (the
calibrator), termed ‘Nmaspin’, were determined as follows:
Nmaspin ¼ 2ðDCtsample DCtcalibratorÞ
where DCt values of the sample and calibrator are determined by
subtracting the average Ct value of the maspin gene from the
average Ct value of the maspin gene.
Primers and PCR consumables Primers for the TBP and maspin
genes were chosen with the assistance of the computer programs
Oligo 4.0 (National Biosciences, Plymouth, MN, USA). We
conducted BLASTN searches against dbEST, htgs and nr (the
nonredundant set of the GenBank, EMBL and DDBJ database
sequences) to confirm the total gene specificity of the nucleotide
sequences chosen for the primers, and the absence of DNA
polymorphisms. The nucleotide sequences of the primers used
were as follows: Maspin-U (50-CTA CTT TGT TGG CAA GTG GAT
GAA-30) and Maspin-L (50-ACT GGT TTG GTG TCT GTC TTG
TTG-30) for maspin gene (PCR product of 90bp), and TBP-U
(50-TGC ACA GGA GCC AAG AGT GAA-30) and TBP-L (50-CAC
ATC ACA GCT CCC CAC CA-30) for TBP gene (PCR product
of 132bp).
To avoid amplification of contaminating genomic DNA, one of
the two primers was placed in a different exon. For example, the
upper primer of TBP was placed at the junction between exons 5
and 6, whereas the lower primer was placed in exon 6. Agarose gel
electrophoresis allowed us to verify the specificity of PCR
amplicons.
Table 1 Characteristics of the 105 ERa-positive postmenopausal
patients and their relation to RFS
RFS
Number of
patients
Number of
events (%)
a P-value
b
Age (years) NS
p70 52 17 (32.7)
>70 53 14 (26.4)
Histological grade
c 0.00067
I+II 80 17 (21.2)
III 24 13 (54.2)
Lymph node status 0.003
0 17 2 (11.8)
1–3 59 14 (23.7)
>3 29 15 (51.7)
Macroscopic tumour size (mm) 0.021
p30 73 17 (23.3)
>30 32 14 (43.7)
Maspin RNA status 0.0011
Underexpressed 33 7 (21.2)
Normal 48 11 (22.9)
Overexpressed 24 13 (54.2)
aFirst relapses (local and/or regional recurrences, and/or distant metastases).
bLog-
rank test. NS=not significant.
cScarff–Bloom–Richardson classification. Information
available for 104 patients.
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yRNA extraction Total RNA was extracted from breast specimens
by using the acid-phenol guanidium method. The quality of the
RNA samples was determined by electrophoresis through agarose
gels and staining with ethidium bromide, and the 18S and 28S RNA
bands were visualised under ultraviolet light.
cDNA synthesis RNA was reverse transcribed in a final volume of
20ml containing 1 RT buffer (500mM each dNTP, 3mM MgCl2,
75mM KCl, 50mM Tris-HCl pH 8.3), 10 units of RNasinTM
Ribonuclease inhibitor (Promega, Madison, WI, USA), 10mM
dithiothreitol, 50U of Superscript II RNase H-reverse transcriptase
(Gibco BRL, Gaithersburg, MD, USA), 1.5mM random hexamers
(Pharmacia, Uppsala, Sweden) and 1mg of total RNA. The samples
were incubated at 201C for 10min and 421C for 30min, and reverse
transcriptase was inactivated by heating at 991C for 5min and
cooling at 51C for 5min.
PCR amplification All PCR reactions were performed using an
ABI Prism 7700 Sequence Detection System (Perkin-Elmer Applied
Biosystems, Foster City, CA). Polymerase chain reaction was
performed using the SYBR
s Green PCR Core Reagents kit (Perkin-
Elmer Applied Biosystems, Foster City, CA). The thermal cycling
conditions comprised an initial denaturation step at 951C for
10min and 50 cycles at 951C for 15s and 651C for 1min.
Experiments were performed with duplicates for each data point.
Immunohistochemical studies
Indirect immunoperoxidase staining of fixed tissues was per-
formed using mouse monoclonal antibody G167-70 directed
against the human maspin protein (PharMingen, San Diego, CA)
and monoclonal antibody SMMS-1 raised against human myosin
heavy chain (Dakocytomation Denmark A/S, Glostrup, DK).
The immunohistochemical procedure was applied to paraffin-
embedded tissue sections. A water bath antigen-retrieval technique
was used in all cases. Sections were mounted on precoated slides
(Dako) and allowed to dry at 501C overnight. The sections were
then dewaxed in xylene and hydrated through graded dilutions of
ethanol. Endogenous activity was blocked with 1% hydrogen
peroxide for 15min. Sections were then immersed in a heat-
resistant plastic box containing 10ml of pH 6.0 citrate buffer and
processed in the water bath for 40min. Sections were then allowed
to cool to room temperature for 20min before rinsing in H2O. The
blocking reagent was poured off and the primary antibodies were
left for 25min. A standard avidin–biotin–peroxidase complex
(LSAB) method was used to reveal the antibody–antigen reaction
(Dako).
The localisation and intensity of staining were assessed by two
independent pathologists who were blinded to the real-time RT–
PCR results.
Statistical analysis
Relapse-free survival (RFS) was determined as the interval between
diagnosis and detection of the first relapses (local and/or regional
recurrences, and/or metastases).
Clinical, histological and biological parameters were compared
using the w
2 test. Differences between the two populations were
judged significant at confidence levels greater than 95% (Po0.05).
The relation between maspin mRNA levels and ERa status was
assessed using the Kruskal–Wallis test. Survival distributions were
estimated by the Kaplan-Meier method (Kaplan and Meier, 1958),
and the significance of differences between survival rates was
ascertained using the log-rank test (Peto et al, 1977). Cox’s
proportional hazards regression model (Cox, 1972) was used to
assess prognostic significance.
RESULTS
Maspin mRNA expression in normal breast tissues
To determine the cutoff point for altered maspin expression in
breast cancer tissue, the Nmaspin value, calculated as described in
Patients and Samples, was determined for eight normal breast
RNA samples (Table 2). As this value consistently fell between 0.59
and 1.67 (mean 1.047s.d. 0.35), values of 3 (mean75 s.d.) or more
were considered to represent marked overexpression, and values of
0.30 (mean 2 s.d.) or less were considered to represent under-
expression of maspin mRNA. We have previously used the same
approach to determine the cutoff points for altered expression of
other tumour genes (Bie `che et al, 1999a).
Relation between maspin mRNA levels and ERa expression
status
Maspin mRNA levels were determined in 10 ERa-negative and 10
selected ERa-positive breast tumours with very high ERa mRNA
values (Table 2). These 10 ERa-negative and 10 ERa-positive breast
tumours have been selected from a previously tested breast
tumours series where the ERa status was determined at the protein
level by biochemical methods and quantified by ERa real-time
quantitative RT–PCR assay (Bie `che et al, 2001).
We found a negative correlation between maspin and ERa
mRNA expression (P¼0.0012): the 10 ERa-negative breast
Table 2 Maspin gene expression in human breast tissues
Sample no. Nmaspin value
Normal breast tissues
P1 0.93
P2 1.06
P3 1.17
P4 1.35
P5 0.73
P6 0.59
P7 0.84
P8 1.67
Mean (s.d.) 1.0470.35
ERa-negative breast tumours
T1 1.62
T2 5.22
T3 3.92
T4 40.3
T5 1.51
T6 3.33
T7 96.8
T8 2.69
T9 1.33
T10 0.89
Mean (s.d.) 15.76730.87
ERa-positive breast tumours
T1 0.78
T2 0.02
T3 0.72
T4 3.89
T5 0.33
T6 0.24
T7 0.47
T8 0.17
T9 0.84
T10 1.26
Mean (s.d.) 0.8771.12
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normal; mean 15.767s.d. 30.87) than the 10 ERa-positive breast
tumours (0.02- to 3.89-fold; mean 0.877s.d. 1.12) (Table 2).
Maspin mRNA expression in a well-defined set of 105 ERa-
positive postmenopausal breast tumour RNA samples
To better assess the prognostic value of maspin gene expression in
ERa-positive breast cancer, we quantified maspin mRNA content
in an additional independent well-defined cohort of 105 ERa-
positive postmenopausal breast cancer patients treated with
primary surgery followed by adjuvant tamoxifen alone. These
breast tumour RNA samples had a wide range of Nmaspin values
(0.01–46.7, i.e. nearly four orders of magnitude).
Compared to normal breast tissues, 57 (54.3%) tumours showed
altered maspin mRNA expression. A total of 33 tumours (31.4%)
showed maspin mRNA underexpression (Nmaspin from 0.01 to 0.28)
and 24 (22.9%) showed maspin mRNA overexpression (Nmaspin
from 3.11 to 46.7).
maspin expression was also investigated in six breast tumour
cell lines. All showed maspin underexpression, with Nmaspin values
of 0.004 (SK-BR-3), 0.029 (T-47D), 0.045 (BT-20), 0.001 (HBL-100),
0.042 (ZR-75-1) and 0.017 (MCF7).
Localisation of maspin protein in epithelial tumour cell
cytoplasm
We detected specific maspin immunoreactivity in normal myo-
epithelial cells of all eight tumour samples studied by IHC. We also
detected strong specific immunoreactivity in epithelial cells of the
four tumours which overexpressed maspin mRNA and in none of
the four tumours which did not overexpress maspin. We thus
obtained a perfect match between maspin mRNA overexpression
and IHC positivity (Figure 1). Maspin immunoreactivity was
exclusively found in normal myoepithelial cells and tumour
epithelial cells; infiltrating lymphocytes and normal glandular
cells in the tumour were consistently negative. Staining was found
exclusively in the cytoplasm of both normal myoepithelial and
tumour epithelial cells (Figure 1). The positive tumour epithelial
cells were myosin heavy-chain-negative (Figure 1), and were
therefore not of myoepithelial origin.
Correlation between maspin mRNA levels and clinical,
pathological and biological parameters
We sought links between maspin mRNA expression status and
standard clinical and pathological factors in breast cancer
(Table 3). The only statistically significant association (w
2 test)
was between maspin mRNA overexpression and Scarff–Bloom–
Richardson (SBR) histopathological grade III (P¼0.03). maspin
mRNA status was not significantly associated with age, lymph
node status, macroscopic tumour size or histological type.
We also found no link between maspin mRNA status and the
mRNA status of two candidate genes predicting the response to
endocrine therapy, namely ERBB2 and ERb (estrogen receptorb)
(Table 3).
Prognosis analysis of maspin mRNA expression
Univariate analysis (log-rank test) showed that RFS was linked to
maspin mRNA status (P¼0.0011; Figure 2). The RFS of the 24
patients with maspin-overexpressing tumours (5-year RFS
41.8710.5%) was shorter than that of the 48 patients whose
tumours normally expressed maspin (5-year RFS 84.475.4%) and
also shorter than that of the 33 patients with maspin-under-
expressing tumours (5-year RFS 83.676.7%).
Interestingly, the outcome of the patients with maspin-over-
expressing tumours was also significantly worse when the analysis
focused on two well-known specific subsets of poor-prognosis
breast cancer patients, that is, those with more than three involved
lymph nodes (P¼0.0049, Figure 3A) and those with histopatho-
logical grade III (P¼0.035, Figure 3B).
Finally, the prognostic significance of the four parameters
identified in univariate analysis (histopathological grade III,
lymph-node status, macroscopic tumour size (Table 1) and maspin
overexpression status (Table 1, Figure 2)) persisted (except for
macroscopic tumour size) in Cox multivariate regression analysis
of RFS (Table 4).
DISCUSSION
Since 1994, when maspin was first described as a tumour-
suppressor gene in breast cancer, little has been learnt about its
expression. Maspin protein is present in the breast epithelium, and
particularly in the myoepithelium, and maspin expression has been
reported to be both decreased and increased in subsets of breast
tumours, and lost in some metastases (Zou et al, 1994; Jiang et al,
1997; Domann et al, 2000). Four clinical studies of maspin
expression have recently been reported, and these mainly focused
on underexpression status, one at the mRNA level (Maass et al,
2001a) and three at the protein level (Hojo et al, 2001; Maass et al,
2001b; Umerika et al, 2002). Maass et al (2001a), using a
semiquantitative nested RT–PCR assay in a small series of
primary breast carcinoma tissues (n¼45) with short follow-up
(3 years), showed no maspin transcripts in 16 (36%) breast
tumours. Maspin mRNA expression was unrelated to established
prognostic factors, including ERa status, but six of the eight
patients who developed distant metastasis within 3 years of the
initial diagnosis showed no maspin mRNA expression in their
primary breast tumours. Two immunochemical studies, although
involving heterogeneous breast tumours series with no follow-up,
also suggest that maspin underexpression could be a marker of
breast cancer aggressiveness (Hojo et al, 2001; Maass et al, 2001b).
In contrast, the third study identified maspin overexpression as an
independent poor prognostic indicator in breast cancer patients
(Umerika et al, 2002).
We used real-time quantitative RT–PCR to assess maspin gene
expression in human breast tumours. This recent approach to
nucleic acid quantification is suited to the development of target
gene assays, having a high degree of inter-laboratory standardisa-
tion and yielding statistical confidence values (Bie `che et al, 1999b).
The main advantage of real-time RT–PCR is its large linear
dynamic range. This made it particularly appropriate for analysing
maspin gene expression, which ranged from 0.01 to 46.7 times
normal in this series. Contrary to Maass et al (2001a), who failed to
detect maspin mRNA in 36% of their breast cancer specimens with
a semiquantitative nested RT–PCR assay, we detected maspin
mRNA in all the breast tumour samples tested, probably reflecting
the higher sensitivity of our real-time RT–PCR method.
It has been suggested that maspin dysregulation in tumours may
be because of altered expressions of various transregulators acting
on the maspin promoter, including the proteins Ets and Ap1
(Zhang et al, 1997) and p53 (Zou et al, 2000). A recent publication
also discussed the involvement of aberrant cytosine methylation
and chromatin condensation of the maspin promoter in the
silencing of maspin expression during neoplastic progression
(Domann et al, 2000).
We found a strong negative correlation between maspin gene
expression and ERa expression status (Table 2), in agreement with
Umerika et al (2002) and Martin et al (2000). These latter authors,
using cDNA array technology, identified maspin gene as the leader
of a cluster of genes that are strongly upregulated in ERa-negative
breast tumours. Thus, to test the prognostic value of maspin
mRNA expression in breast cancer, we chose to analyse a well-
defined cohort of 105 postmenopausal patients with ERa-positive
Maspin expression in breast cancer
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tamoxifen alone.
We observed both underexpression (31.4% of samples) and
overexpression (22.9%) of maspin mRNA.
In all, 33 tumours, and all six breast tumour cell lines tested (SK-
BR-3, 47D, BT-20, HBL-100, ZR-75-1 and MCF7) underexpressed
maspin mRNA. These results are in agreement with reports from
several authors (Zou et al, 1994; Domann et al, 2000; Maass et al,
2001a) showing maspin underexpression at the RNA and/or
protein level in breast cancer, and corroborating biological
evidence that maspin is a tumour-suppressor gene. The very low
maspin mRNA values in the six breast tumour cell lines tested by
real-time RT–PCR were in total agreement with previous data
(Zou et al, 1994; Zhang et al, 1997; Domann et al, 2000; Maass et al,
2001a). These very low values observed in the tumour cell lines
could be because of the depletion in the in vitro epithelial breast
tumour cell cultures of the myoepithelial normal cells, which
secrete high levels of maspin (Sternlicht and Barsky, 1997).
Contrary to Maass et al (2001a), but in agreement with Martin et al
(2000) and Umerika et al (2002), we found an association between
Figure 1 Immunohistochemical staining for maspin (A, B, E, F) and for myosin heavy chain (C, D) in two breast tumours, one with normal maspin
expression (A, C, E) and one with maspin overexpression (B, D, F). Intense maspin immunoreactivity was found in tumour epithelial cells from the maspin
mRNA-overexpressing tumour (B) but not in cells (star) from the tumour without maspin overexpression (A) (original magnification  20). Note the
negative myosin heavy-chain staining of tumour epithelial cells from the maspin mRNA-overexpressing tumour (D), confirming that the latter is not of
myoepithelial origin (original magnification  20). In both cases, normal breast tissue showed maspin immunoreactivity in normal myoepithelial cells (arrows)
(A, B), which also showed strong immunoreactivity for myosin heavy chain (C, D) (original magnification  20). Maspin immunoreactivity was localised in
the cytoplasmic compartment of both epithelial tumour cells (F) and normal myoepithelial cells (E) (original magnification  100).
Maspin expression in breast cancer
I Bie `che et al
867
British Journal of Cancer (2003) 88(6), 863–870 & 2003 Cancer Research UK
M
o
l
e
c
u
l
a
r
a
n
d
C
e
l
l
u
l
a
r
P
a
t
h
o
l
o
g
ymaspin mRNA underexpression and oestrogen receptor alpha
positivity, suggesting that maspin mRNA underexpression is
associated with low tumour aggressiveness (Table 2).
Finally, RFS after surgery was not shorter in patients whose
tumours underexpressed maspin than in patients whose tumours
normally expressed maspin (Figure 2). Zou et al (1994) and Sheng
et al (1996) reported that maspin inhibited the invasive and
metastatic potential of breast cancer cells, while Maass et al
(2001a) found that maspin downregulation was associated with a
higher risk of early distant metastasis in a series of breast tumour
patients with short median follow-up (3 years).
We also identified 24 tumours with clear maspin overexpression,
mRNA expression ranged from 3.1- to 47-fold that was found in
normal breast tissue. Several authors have previously reported
cases of maspin-overexpressing breast tumours (Hojo et al, 2001;
Maass et al, 2001b; Umerika et al, 2002). By using immunohis-
tochemical analysis, we showed that maspin transcripts are
translated into maspin protein (Figure 1). We also showed a
positive correlation between maspin mRNA overexpression and
maspin protein abundance, and precised that alteration of maspin
gene expression was exclusively found inside tumour epithelial
cells (Figure 1). Taken together, these findings suggest that maspin
gene expression is mainly dysregulated at the transcriptional level
in breast cancer. It is also noteworthy that we found weaker
maspin immunoreactivity in normal myoepithelial cells located in
adjacent normal breast tissue found around all the tumour samples
tested, in keeping with the literature (Sternlicht and Barsky, 1997).
In our ERa-positive postmenopausal breast tumour series,
maspin mRNA overexpression was associated with poor long-
term patient outcome relative to tumours with normal or low
maspin expression (Figure 2). We also obtained evidence that
maspin mRNA overexpression might be a further marker of poor
outcome in patient subsets with classical markers of poor
prognosis (more than three involved lymph nodes, or histopatho-
logical grade III) (Figure 3).
Table 3 Relation between maspin mRNA level and the standard clinical, pathological and biological factors
maspin mRNA level
Number of patients (%)
Total population (%) Underexpression Normal Overexpression P-value
a
Total 105 (100.0) 33 (31.4) 48 (45.7) 24 (22.9)
Age (years) NS
p70 52 (49.5) 15 (45.5) 27 (56.2) 10 (41.7)
>70 53 (50.5) 18 (54.5) 21 (43.8) 14 (58.3)
Histological grade
b,c 0.03
I+II 80 (76.9) 27 (81.8) 40 (83.3) 13 (56.5)
III 24 (23.1) 6 (18.2) 8 (16.7) 10 (43.5)
Lymph node status NS
0 17 (16.2) 5 (15.2) 7 (14.6) 5 (20.8)
1–3 59 (56.2) 15 (45.4) 32 (66.7) 12 (50.0)
>3 29 (27.6) 13 (39.4) 9 (18.7) 7 (29.2)
Macroscopic tumour size (mm) NS
p30 73 (69.5) 22 (66.7) 34 (70.8) 17 (70.8)
>30 32 (30.5) 11 (33.3) 14 (29.2) 7 (29.2)
Histological type NS
Ductal 97 (92.4) 32 (97.0) 42 (87.5) 23 (95.8)
Lobular 8 (7.6) 1 (3.0) 6 (12.5) 1 (4.2)
ERBB2 RNA status NS
Overexpressed 18 (17.1) 3 (9.1) 8 (16.7) 7 (29.2)
Normal 87 (82.9) 30 (90.9) 40 (83.3) 17 (70.8)
ERb RNA status
c NS
Low 36 (34.6) 14 (42.4) 15 (31.9) 7 (29.2)
Intermediate 34 (32.7) 7 (21.2) 17 (36.2) 10 (41.6)
High 34 (32.7) 12 (36.4) 15 (31.9) 7 (29.2)
aw
2-test.
bScarff–Bloom–Richardson classification.
cInformation available for 104 patients.
Figure 2 Relapse-free survival curves for patients with maspin-over-
expressing, normally expressing and underexpressing tumours.
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usual treatment for ERa-positive postmenopausal breast cancer.
Our results, obtained in a well-defined cohort of ERa-positive
postmenopausal breast cancer patients treated in this way, also
suggest that maspin status, by evenly dichotomising such patients,
might emerge as a useful predictor of the response to endocrine
therapy. Moreover, the predictive power of maspin expression
appears to be independent of two other genes, ERBB2 and ERb,
which have been proposed to predict the response to endocrine
therapy (Speirs et al, 1999; Stal et al, 2000). Indeed, we found no
link between maspin mRNA status and the mRNA status of these
two genes (Table 3). Confirmation of the predictive value of
maspin parameter in the response to endocrine therapy in breast
cancer patients needs a prospective randomised study to show that
this parameter do influence the outcome only in patients who
received adjuvant tamoxifen as compared with untreated patients.
This relation between maspin gene overexpression and poor
outcome in breast cancer is in agreement with Umerika et al
(2002), but conflicts with the reported role of maspin as a tumour-
suppressor gene that inhibits cell migration and angiogenesis.
Maass et al (2001c), in a series of pancreatic tumours, found that
maspin expression was gradually upregulated with increasing
malignancy, from normal pancreas tissue to precancerous lesions
and invasive carcinoma. One possible explanation for these
paradoxical results is that maspin expression is upregulated in
order to neutralise for overexpression of tumour-activating gene
targets. It is noteworthy in this respect that other inhibitors of
tumour progression, such as PAI-1 and PAI-2 (plasminogen
activator inhibitor type 1 and type 2) are overexpressed in breast
cancer and associated with a poor prognosis (Stephens et al, 1998).
These results confirm the interest to investigate maspin gene
expression for the detection of circulating breast tumour cells or of
submicroscopic lymph-node metastases in breast cancer patients
(Merrie et al, 1999; Sabbatini et al, 2000). These new informations
concerning maspin overexpression in breast cancer associated with
a poor prognosis also call into question the use of this gene or its
product to inhibit angiogenesis or metastasis.
In conclusion, the results of this study point to a major role of
the maspin gene in ERa-positive breast cancer. In particular, we
obtained evidence that maspin mRNA status might serve as a new
prognostic marker, and also as a possible predictor of the response
to endocrine therapy in postmenopausal breast cancer patients.
Finally, we describe a rapid, highly sensitive, high-throughput
RT–PCR assay for determining maspin mRNA status.
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